Compare Amgen, Inc. (AMGN) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs New York Times Co — how do they compare? Amgen, Inc. trades at $356 (market cap $196.12B), while New York Times Co trades at $76.89 (market cap $12.13B). The key difference: Amgen, Inc. is far larger — about 16.2× New York Times Co's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | NYT | |
|---|---|---|
Market Cap | $196.12B | $12.13B |
Sector | Health | Media |
52-Week High | $388.16 | $85.86 |
52-Week Low | $271.18 | $51.43 |
Enterprise Value | $241.41B | $11.53B |
Dividend Yield | 2.77% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
The New York Times (NYT) stock trades at $74.96, up 0.89% on the day, reflecting steady growth. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $0.61 surpassing the $0.47 expectation. Revenue reached $2.82B in 2025, with net income margin improving to 12.17%. Technical indicators show a bullish trend, while analyst consensus is a $78 price target. Recent news highlights legal actions involving OpenAI and government subpoenas, adding to operational scrutiny.
Outlook remains positive due to strong earnings performance and revenue growth, but risks include legal battles and regulatory pressures. The stock offers potential upside to the consensus target, supported by solid cash flow and profitability metrics. Investors should weigh these factors against ongoing litigation and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
